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Introduction: Gout is a common and disabling cause of arthritis in middle-aged and elderly 
populations, with its main predisposing factor being hyperuricemia (serum urate  6.8 mg/dL). 
Options for treatment of chronic gout until 2008 were allopurinol, a xanthine oxidase inhibitor, and 
the group of drugs known as uricosurics that stimulate the renal excretion of uric acid. A proportion 
of patients, including some with chronic kidney disease and solid organ transplantations, could 
not be treated with the those therapies because of intolerance, drug interactions, or adverse events. 
Febuxostat is a nonpurine xanthine oxidase inhibitor, recently approved in Europe and the United 
States for the treatment of chronic gout.
Aim: To review the clinical evidence (phase II and III studies) of the effectiveness and safety 
of febuxostat for treatment of hyperuricemia and gout.
Evidence review: Febuxostat, at doses ranging from 40 to 240 mg/day, is efficacious in reduc-
ing serum urate in patients with hyperuricemia and gout, comparing favorably with fixed doses 
of allopurinol in that respect. Early safety signals with respect to liver test abnormalities and 
cardiovascular outcomes have not been confirmed in recent large prospective trials but need 
to be further monitored.
Clinical potential: Given its low cost and extensive clinical experience, allopurinol will 
likely remain the first-line drug for management of hyperuricemia and gout. Febuxostat may 
provide an important option in patients unable to use allopurinol, those with very high serum 
urate levels, or in the presence of refractory tophi.
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Core evidence outcomes summary for febuxostat in hyperuricemia and gout
Outcome measure Evidence Implications
Patient-oriented evidence
Reduction in gout flares Moderate An expected increase in gout flares was shown with 
initiation of treatment  
A subsequent reduction with continuous therapy is 
suggested by clinical trials but this has not been the 
primary outcome in any study 
No superiority compared to allopurinol has been 
demonstrated
reduction in tophi numbers  
or volume
Moderate Studies and abstracts suggest a reduction in tophi size,  
limited evidence of superiority against allopurinol in  
this respect
Drug is free of serious  
adverse effects
Moderate important safety signals raised by clinical studies have 
not been confirmed in recent large prospective trials 
Postmarketing surveillance will be required
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Scope, aims, and objectives
The aim of this article is to review the clinical evidence 
of the effectiveness of febuxostat (TEI-6720, or TMX-67) 
on outcomes and its potential for clinical management of 
hyperuricemia and gout.
Methods
This review analyzes phases II and III evidence of febuxostat 
in the management of gout. Literature searches were performed 
using PubMed (www.pubmed.gov 1950–November 2008) and 
the Cochrane database (www.cochrane.org) with the search 
terms “febuxostat” OR “TEI-6720” OR “TMX-67” (Table 1):
•  75 references were identified
•  eight were clinical trials
•  five phase I studies, one phase II trial, and two phase III 
trials.
Additionally, abstracts from the American College of 
Rheumatology meetings (available at www.rheumatology.org, 
years 2001–2008) and European League Against Rheumatism 
meetings (available at www.eular.org, years 2001–2008) 
were browsed using the terms “febuxostat” OR “TEI-6720” 
OR “TMX-67”:
•  24 abstracts were identified
•  seven were phase II or III clinical trials
•  six abstracts were ancillary studies, performed with data 
previously collected on phase II or III trials
•  three abstracts were extensions of phase II or III trials.
Ongoing or unfinished studies were searched from the 
federal database (www.clinicaltrials.gov). Only one study, 
recently completed and presented at the meeting of the 
American College of Rheumatology was identified. The 
economic evidence from the report of the National Institute 
of Clinical Excellence (NICE) from the UK (www.nice.
org.uk) is also discussed.
Disease overview
Uric acid (or urate) is the end product of purine metabolism 
in humans and several other higher primates. Concentrations 
of urate beyond its limit of solubility in serum [6.8 mg/dL at 
37 °C (404 µmol/L)] defines hyperuricemia,1 a necessary but 
not sufficient factor for the development of gout, the disease 
state characterized by tissue deposition of monosodium urate 
(MSU) crystals and its associated symptoms.
Gout is a common diagnosis in Western populations. 
According to the most recent estimate by the National Arthritis 
Data Workgroup using 1996 data from the National Health 
Interview Survey (NHIS) and National Health and Nutrition 
Examination Survey (NHANES) in the US, 3 million adults 
older than 18 years had gout in the past year and 6.1 million 
adults over 20 years old have been diagnosed with gout at 
some point in their lives.2 The incidence of gout has been 
increasing in the US3 and is currently considered the most 
common inflammatory arthritis in men over 40 years old, 
exceeding rheumatoid arthritis.2 Worldwide, gout frequencies 
(Continued)
Outcome measure Evidence Implications
improvement in quality of life No evidence
Disease-oriented evidence
Effective control  
of hyperuricemia
Clear Febuxostat is effective in reducing serum urate levels  
in patients with hyperuricemia and gout 
it compares favorably at multiple dosages with  
fixed-dose allopurinol (300 mg/day)
Economic evidence
Cost effectiveness as 
treatment of hyperuricemia 
and gout
Limited Incremental cost-effectiveness ratio £15 565–16 574 
($US24 342–25 920) per quality-adjusted life-year, 
but acquisition costs likely to be much higher than 
generic allopurinol
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 67 23
  records excluded 65 11
  records included 2 12
Additional studies identified 0 0
Level 1 clinical evidence 0 0
Level 2 clinical evidence 2 3
Level  3 clinical evidence 0 9
  Studies other than rCT a 9
  Case reports 0
Economic evidence 0 0
Notes: aOpen label or nonrandomized studies conducted with data collected from 
phase ii or iii clinical trials; published only in abstract form.
For definitions of levels of evidence see Core Evidence website (http://www.dovepress.
com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4 27
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and time trends are heterogeneous with high prevalence in 
specific populations like Malayo-Polynesians (1.7%)4 and 
New Zealand Maoris (8.8%).5
A definitive diagnosis of gout is confirmed by the 
observation of intracellular needle-shaped, negatively 
birefringent crystals on synovial fluid aspirated from an 
affected joint or the presence of tophi (tissue deposits of 
crystallized monosodium urate that are usually evident 
under the skin of patients with chronic hyperuricemia). 
The disease is characterized by recurrent attacks of pain 
and swelling in the affected joints. If the hyperuricemia 
underlying the disease is not treated, the disease can 
progress into a chronic stage leading to chronic pain, 
significant impairment in quality of life, and disability.6–8 
Clinical and radiographic features can contribute to the 
diagnosis in cases with atypical presentations. The burden 
of disease is considerable in patients with solid organ 
transplants, mainly because of the hyperuricemic effect 
of cyclosporine.9 Affected patients frequently suffer 
from multiple comorbidities and polypharmacy, making 
management of acute flares and chronic hyperuricemia 
difficult because of intolerances to first-line agents and 
drug interactions.
Current therapy options  
for chronic gout
The management goals in gout differ depending on the 
setting and stage of the disease. In acute gout pharmacologic 
treatment is aimed at resolving the prominent pain and 
inflammation. In the intercritical periods (asymptomatic 
periods in between gout flares) the goal is to maintain serum 
urate at subsaturation levels preventing the development 
of tophi, and preventing the recurrence of new attacks 
through prophylactic management. A list of the agents 
currently available for management of gout is presented 
in Table 2.
Pharmacologic options  
for chronic hyperuricemia and gout
This section deliberately excludes a discussion on febuxostat, 
that will be discussed extensively in the following sections. 
The decision about initiating long term therapy for 
hyperuricemia and gout prevention should be individualized. 
Currently, there is no evidence that treating asymptomatic 
hyperuricemia alone is efficacious or cost effective. However, 
very high levels of serum urate place individuals at a very 
high risk for incident gout10 and, at a minimum, lifestyle 
changes including reduction in alcohol intake, dietary 
changes, and weight loss should be considered. Additionally, 
a reassessment of the need for other pharmacologic therapies 
that could be affecting serum urate levels like diuretics 
should be considered.11,12 After a single episode of acute gout, 
long-term urate-lowering therapy may not yet be indicated, 
as joint damage is unlikely to occur in patients who remain 
asymptomatic. However, there is reasonable consensus that 
long-term therapy is advocated in patients with two or more 
flares per year or with tophi.11–14
The goal of chronic urate-lowering therapy should be to 
reduce serum urate until the goal of a subsaturation concen-
tration of uric acid at or about 6.8 mg/dL or less is reached 
(a more ambitious goal of 6.0 mg/dL or less is recommended 
according to recent guidelines).11 Hyperuricemia develops 
secondary to either overproduction (excretion of more 
than 600 mg/day in the urine; accounting for 10%–15% of 
hyperuricemia cases) or underexcretion (excretion of less 
than 330 mg/day; approximately 85%–90% of hyperuricemia 
cases).1 Both overproduction and underexcretion could be 
primary, such as in the inherited enzymatic disorders of 
urate production (hypoxanthine-guanine phosphoribosil 
transferase defect or phosphoribosilpyrophosphatase synthe-
tase [PRPP] overactivity) or the condition known as familial 
juvenile hyperuricemic nephropathy. Common secondary 
or acquired causes of overproduction and underexcretion 
Table 2 Therapeutic agents for management of gout
Acute gout flares •  Nonpharmacologic: icepacks
•  Nonsteroidal anti-inflammatory drugs
•  Colchicine
•  Glucocorticoids
•  Cosyntropin (ACTH derivative)
Urate-lowering agents for chronic gout •  Xanthine-oxidase inhibitor: allopurinol, febuxostat
•  Uricosuric agents: probenecid, sulfinpyrazone, benzbromarone
•  Other agents with urate-lowering properties: fenofibrate, losartan
Abbreviation:  ACTH, adrenocorticotropic hormone.Core Evidence 2009:4 28
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are due to excessive purine turnover (diet, malignancies), 
medications, and toxins. Distinguishing between serum urate 
overproducing and underexcreting gout patients may have 
therapeutic significance but does not need to be routinely 
performed.15 Concomitant use of colchicine or NSAIDs 
during the initiation of urate-lowering may be needed to 
prevent rebound flares.11,16
Xanthine oxidase inhibitors
Allopurinol is the preferred urate-lowering agent in view 
of its efficacy in overproducers and underexcretors of 
serum urate, relatively easy dosing regimen, low cost, and 
generally acceptable safety profile. Allopurinol and its 
metabolite oxypurinol are both substrates and inhibitors of 
xanthine oxidase, blocking the conversion of hypoxanthine 
to xanthine to uric acid.17 Both lower serum and urinary 
urate levels. The recommended starting dose of allopurinol 
is 100 mg/day with progressive increases in the dosage 
every 2–4 weeks until reaching a target of 300 mg/day.11 
However, it is common practice to start treatment fixed at 
dosages ranging from 50–300 mg/day depending on fac-
tors such as renal function, age, and comorbidities. Lower 
initial doses are preferred because an expected lower fre-
quency of acute gout flares and hypersensitivity reactions 
after initiation of therapy. It is important to monitor serum 
urate levels regularly for dosage adjustments until the target 
concentration is reached. There is no evidence about how 
often this monitoring should be done, but it makes sense 
to know the serum urate concentration before each dose 
increase during the titration phase to make sure the patient 
is not already at goal; a goal that some patients may reach 
with doses as low as 100–200 mg/day.18 Allopurinol should 
be started at a lower dose in elderly patients and those with 
impaired kidney function. However, renal adjusted doses 
usually fail to achieve target serum urate levels and con-
tinuous titration of the drug to the goal should be carefully 
attempted.19 The most commonly used allopurinol dose of 
300 mg/day achieves target serum urate concentrations in 
only 53% of patients20 and dosages as high as 800 mg/day 
(the highest dose recommendation by the FDA) or even 
up to 1200 mg/day are occasionally necessary. However, 
before escalating the dose to very high levels adherence 
should be assessed because as many of 50% of patients 
are noncompliant with the medication,21 especially if 
they are having recurrent gout flares. The major barrier to 
achieve optimal disease control with allopurinol is under 
dosing. This is possibly due to a lack of awareness of target 
serum urate and concerns about the safety of the drug in 
the primary care setting, where most of the gout care is 
usually provided.22,23
Adverse reactions from allopurinol are generally 
uncommon and most are mild. The most frequent toxicities 
are rash, gastrointestinal intolerance such as diarrhea, 
headache, and leukopenia. Rashes can be recurrent on 
reexposure to the drug and an important cause of intoler-
ance. Although in general very rare, allopurinol exposure 
is one of the most common causes of toxic epidermal 
necrolysis and Stevens-Johnson syndrome.24 Given the 
scarcity of treatment alternatives for certain patients, allo-
purinol desensitization protocols have been developed.25 
The allopurinol hypersensitivity syndrome is an uncom-
mon immune-mediated severe reaction with mortality of 
up to 20%. It is characterized by fever, rash, acute renal 
insufficiency, eosinophilia, hepatic injury, and vasculi-
tis. Renal impairment, diuretic use, and recent initiation 
of allopurinol have been implicated in the development 
of allopurinol hypersensitivity syndrome.26–29 In a case 
series of 78 patients with a creatinine clearance of less 
than 10 mL/min there was virtually no renal excretion of 
the main allopurinol metabolite, oxypurinol.28 Along the 
same line, cases of allopurinol hypersensitivity have been 
linked to T cell mediated immune reactions to oxypurinol,30 
possibly induced by certain human leukocyte antigen 
(HLA) haplotypes like the strong association described 
with HLAB5801 in Han Chinese population.31
Multiple drug interactions may be an additional 
factor limiting the use of allopurinol; notably allopurinol 
can increase drug levels of theophylline, warfarin, and 
azathioprine, the latter regarded, except in rare instances, 
a contraindication.32 Thiazide diuretics can inhibit the 
excretion of allopurinol and potentiate allopurinol toxicity.13 
Finally, a high incidence of skin rashes has been described 
with the combination of ampicillin or amoxicillin with 
allopurinol.33
Uricosuric agents
Uricosuric drugs reverse the most common physiologic 
abnormality in gout, namely, underexcretion of uric acid 
(less than 330 mg of uric acid/24 hours on a regular diet). 
Probenecid and sulfinpyrazone are used internationally, with 
benzbromarone (never available in the US) being recently 
withdrawn from the market in the countries where it was 
available by its principal manufacturer, because of hepatic 
toxicity.34 Other drugs with mild uricosuric effects include 
losartan and fenofibrate. Uricosuric agents probably act at the 
level of the URAT-1 transporter in the proximal tubule.35 When Core Evidence 2009:4 29
Febuxostat: outcomes review Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
used on ideal patient candidates, probenecid, sulfinpyrazone, 
and benzbromarone can be successful 70%–80% of the 
time in achieving optimal serum urate levels.36 However, 
several limitations are encountered when trying to use 
uricosurics in practice. First, they rapidly lose effectiveness 
as the glomerular filtration rate drops below 50 mL/min. 
A potential exception to this rule is benzbromarone, which 
can remain effective in mild to moderate renal impairment 
at the cost of an increased incidence of hepatic toxicity.34 
Second, their use is strongly discouraged in patients with 
history of renal calculi as the uricosuric agents may further 
promote nephrolithiasis. Lastly, their use is not recommended 
in elderly patients, those on multiple medications (because 
of multiple drug interactions), or in patients who have 
trouble complying with multiple daily doses. For example, 
probenecid has known interactions with azathioprine, 
rifampin, salicylates, penicillins, indomethacin, and heparin.36 
Probenecid is the most widely used uricosuric; usually 
initiated at a dose of 500 mg orally twice a day, the dosage 
can be slowly increased up to 3 g/day. Adverse effects include 
gastrointestinal intolerance, rash, hepatotoxicity, acute gout 
attacks, nephrolithiasis, and nephrotic syndrome.37,38
Unmet needs with older therapies
Few drugs are available for long-term urate-lowering therapy. 
Uricosurics are of limited application because of the high 
frequency of comorbidities (particularly renal, which render 
their use ineffective) and drug interactions, significantly 
limiting their use in real clinical practice. Only one approved 
drug, allopurinol, targets the overproduction mechanism of 
hyperuricemia and its use is limited in some cases by drug 
interactions, intolerance, and adverse reactions, one of which, 
the allopurinol hypersensitivity syndrome, is very serious.
There are a number of patients with gout in whom 
no approved alternative for management of their chronic 
hyperuricemia is available because of allopurinol or uricosuric 
intolerances, allergies, or ineffectiveness. A significant 
proportion of these patients have kidney dysfunction or solid 
organ transplantations, with the management of the disease 
being limited only to relief of persistent attacks. Some of these 
patients have chronic tophaceous gout that requires long-term 
glucocorticoids, with its known metabolic and bone health 
consequences, besides the negative impact on quality of life.
There has been a clear need for more alternatives in 
patients with gout in whom allopurinol is contraindicated 
or not tolerated. Until February 2009, no new drugs had 
been approved for gout in the US since allopurinol was 
introduced in 1964.
Clinical evidence of the efficacy  
of febuxostat in the treatment  
of gout
Febuxostat is an orally administerd, nonpurine selective 
inhibitor of xanthine oxidase. The drug acts by binding into a 
channel in the molybdenum center of the enzyme, leading to 
a very stable and long-lived enzyme-inhibitor interaction with 
both the oxidized and reduced forms of the enzyme and, as a 
consequence, a strong inhibition of substrate binding.39
Phase ii data
Only one phase II study has been published investigating 
febuxostat.40 Three ancillary studies and two reports of open-
label extensions of this trial are available in abstract form 
only. One other phase II study from Japan is available also 
only in abstract form.
Becker et al40 conducted a 28-day, multicenter, double-
blind, placebo-controlled, dose response clinical trial to 
determine the safety and efficacy of once daily febuxostat 
(at doses of 40, 80, and 120 mg) in reducing serum uric acid 
(SUA) in patients with American College of Rheumatology 
criteria-defined gout aged 23–80 years old. Several exclusion 
criteria, including absence of patients with kidney dysfunc-
tion or taking drugs known to affect serum urate (such as 
aspirin or diuretics), made this a selected population with 
limited generalizability. A total of 153 patients were finally 
enrolled and randomly assigned to placebo or one of the 
three study drug arms.
A greater proportion of patients in the three febuxostat 
arms achieved target SUA levels of 6.0 mg/dL or less. In 
most cases this reduction was seen as early as 7 days after 
starting the drug and maintained throughout the study period. 
There was a dose-dependent effect of febuxostat, with more 
patients assigned to the higher doses of the drug achieving 
SUA of 5.0 mg/dL and 4.0 mg/dL. As expected and possibly 
as a consequence of sudden removal and mobilization of 
uric acid crystals from the tissues, the incidence of gout 
flares, despite pretreatment with colchicine, was higher in 
the febuxostat 80 mg/day and 120 mg/day arms than with 
placebo. Diarrhea and abdominal pain were side effects 
reported in patients taking febuxostat, but the frequency was 
not different from that with placebo. Abnormal liver function 
test results were reported in five (14%), three (8%), and three 
(8%) of the patients taking febuxostat 40, 80, and 120 mg/day, 
respectively. The authors concluded that there was a prompt 
and persistent efficacy of febuxostat in lowering SUA 
concentrations in patients with hyperuricemia and gout.Core Evidence 2009:4 30
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The three ancillary studies based on this study and 
published only in abstract form described reductions in tophi 
volume (measured by magnetic resonance imaging) in nine 
patients with decreased SUA levels while on febuxostat,41 good 
tolerance of febuxostat in allopurinol-intolerant patients,42 
and need for at least 3 months colchicine prophylaxis in 
patients starting febuxostat.43 Two abstract reports of open-
label extensions up to 48 months describe continuous effi-
cacy of febuxostat in achieving and maintaining an SUA of 
less than 6.0 mg/dL, along with a reduction in gout flares 
and tophi. Adverse reactions mentioned include diarrhea, 
gastrointestinal motility disorders, headache, abnormal liver 
function tests, and hyperlipidemia.44,45 No descriptions of the 
frequencies of these reactions were provided.
A phase II abstract from Japan reported a trial in 
which 128 patients with gout and/or hyperuricemia were 
randomized to placebo or one of three febuxostat dosages 
(10, 20, or 40 mg/day).46 All dosages of febuxostat reduced 
SUA in patients with gout and/or hyperuricemia, regardless 
of whether they were underexcretors or overproducers of 
serum urate. Febuxostat was reported to be safe and well 
tolerated, with main adverse effects being abnormal liver 
function tests and gout flares.
Phase iii data
Two phase III trials have been published in peer-reviewed 
journals and one has recently become available in abstract 
form only. Three ancillary studies and an open-label exten-
sion of these trials are available in abstract form only. Two 
phase III studies from Japan are also available only in 
abstract form.
The Febuxostat versus Allopurinol Controlled Trial 
(FACT)47 was a randomized, double-blind, 52-week, mul-
ticenter trial aimed at evaluating the efficacy and safety 
of febuxostat 80 and 120 mg once daily compared with 
allopurinol at a fixed dose of 300 mg/day in adult patients 
with American College of Rheumatology-defined gout and a 
SUA concentration of at least 8.0 mg/dL (480 µmol/L). Main 
exclusion criteria included kidney dysfunction, concomitant 
drugs known to affect serum urate (eg, urate-lowering agents, 
aspirin, or diuretics), very high body mass index (50), 
active liver disease, pregnancy, use of prednisone at more 
than 10 mg/day, or alcohol abuse. The primary endpoint was 
the achievement of an SUA concentration of 6.0 mg/dL or 
less at each of the last three monthly evaluations. Secondary 
endpoints included achievement of an SUA of 6.0 mg/dL 
or less at each visit and the percentage reduction in SUA 
concentration at each visit. Clinical endpoints included 
reduction in tophus area, change in number of tophi, and 
proportion of patients requiring treatment for acute gout 
flares from weeks 9 to 52.
A total of 1283 patients were screened and 762 were 
randomized to allopurinol or one of the two febuxostat 
arms. Prophylaxis of gout flares with colchicine or naproxen 
was administered to all patients during a 2-week washout 
period and the first 8 weeks of the double-blind treatment 
period. There were no significant differences between 
groups after randomization, with a strong predominance 
of middle-aged (mean age 51–52 years old) white patients 
(75%–79% of patients in all groups). Mean SUA ranged 
from 9.80 to 9.90 mg/dL and years since gout diagnosis 
from 11.5 to 12.6 years. A larger proportion of patients in 
the febuxostat arms than in the allopurinol arm discontinued 
the interventions before study completion: 88 (34%) with 
febuxostat 80 mg/day, 98 (39%) with febuxostat 120 mg/day, 
and 66 (26%) with allopurinol. Most of these discontinuations 
were due to losses to follow-up, but higher proportions of 
adverse events and gout flares leading to discontinuation were 
seen with febuxostat compared with allopurinol.
The primary endpoint of achievement of a SUA of 
6.0 mg/dL or less in the last three visits was significantly more 
frequent in the two febuxostat arms (53% of patients in the 
80 mg/day arm and 62% of patients in the 120 mg/day arm) 
compared with allopurinol (21%). The secondary endpoints 
were also significantly more frequently achieved in the 
febuxostat arms. There were significantly larger proportions 
of patients suffering from at least one gout flare from the 
beginning of therapy through week 8 in the febuxostat 
120 mg/day group (36%) compared with allopurinol (21%), 
but these proportions became similar in the analysis from 
week 9 through week 52 (range 64%–70%). The incidence 
of flares reduced gradually; by week 49–52, the final visit 
interval, the incidence was 8% with febuxostat 80 mg, 6% 
with febuxostat 120 mg and 11% with allopurinol. There 
was no significant difference in the reduction in tophi areas 
between groups.
The rates of total adverse events and serious adverse 
events were reported as similar between the groups. Most 
frequently reported adverse events were liver function 
test abnormalities (range 4%–5%), diarrhea (3% in all 
three groups), and headaches (range from 1%–3%). It is 
very important to note that two patients in the febuxostat 
80 mg/day arm and two in the febuxostat 120 mg/day arm 
died during the study period (two from cardiovascular 
events) versus none in the allopurinol arm. These events 
were considered unrelated to the administration of the study Core Evidence 2009:4 31
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medication by the investigators. The authors’ conclusion 
was that all urate-lowering endpoints requiring an SUA 
concentration of 6.0 mg/dL or less were achieved by more 
febuxostat than allopurinol recipients, but the clinical 
outcomes (reduction in gout flares and tophi area) were 
not different.
A second phase III trial of febuxostat has been recently 
published and expanded upon the results of the FACT study. 
Named Allopurinol and Placebo-Controlled, Efficacy Study 
of Febuxostat (APEX), it was a randomized, double-blind, 
allopurinol and placebo-controlled trial that followed 
1072 subjects for 28 weeks.48 The objective of the study 
was to compare the safety and efficacy of febuxostat at 
dosages of 80, 120, and 240 mg/day with allopurinol or 
placebo. Additionally, an assessment of the effects of 
treatment with febuxostat in patients with impaired renal 
function was sought, and those with mild to moderate renal 
dysfunction (serum creatinine up to 2.0 mg/dL) were allowed 
to participate in the study. The fixed doses in the allopurinol-
controlled arm were divided according to the renal function as 
follows: 300 mg/day was administered to patients with serum 
creatinine up to 1.5 mg/dL, and 100 mg/day to patients with 
serum creatinine between 1.5–2 mg/dL. To be eligible for 
the study, patients needed to be between 18 and 85 years of 
age, have American College of Rheumatology-defined gout, 
hyperuricemia with an SUA of  8.0 mg/dL, and a creatinine 
level up to 2.0 mg/dL as described above. Exclusion criteria 
included intolerances to allopurinol, colchicine, or naproxen; 
history of renal calculi, heavy alcohol intake, baseline hepatic 
transaminases 1.5 the upper limit of normal; and any other 
significant medical conditions as defined by the investigators. 
The study endpoints were similar to the ones described above 
for the FACT study.
Of the 1641 patients screened 1072 were finally 
randomized to the five arms of the study and the same number 
analyzed under an intention-to-treat protocol. A statistically 
larger number of premature withdrawals were found in the 
febuxostat 80 mg/day and febuxostat 240 mg/day arms, 
with the latter group having a larger number of withdrawals 
because of gout flares. The baseline characteristics of the 
patients showed a large majority of middle-aged white 
males (mean ages 51–54 years across groups). Important 
proportions of patients were obese (62%) and hypertensive 
(33%). The mean duration of gout was 10.9 years, and 20% 
of patients had tophi across the different randomized groups. 
The mean baseline serum urate was 9.85 ± 1.26 mg/dL. 
Only 4% of subjects had an impaired renal function (serum 
creatinine of 1.5–2 mg/dL). Significantly greater proportions 
of patients in all the febuxostat arms achieved the primary 
study endpoint of having the last three SUA levels measured 
at 6.0 mg/dL when compared with either allopurinol or 
placebo. It was revealing that a small proportion of patients 
in the allopurinol arm achieved the primary goal (∼20% 
of the overall intention-to-treat population), emphasizing 
the concept that a fixed dose of allopurinol is not sufficient 
to treat most cases of hyperuricemia associated with gout. 
Within the small number of patients with renal dysfunction, 
febuxostat was also significantly more effective in achieving 
the primary efficacy endpoint than allopurinol or placebo. 
More gout flares were present in the febuxostat 120 mg/day 
and 240 mg/day arms in the initial 8 weeks of the study, with 
similar rates among groups in weeks 8–28.
The pattern of adverse events reported in the APEX 
trial were similar to the ones reported previously in the 
FACT study, including diarrhea (6%–13%, depending of 
the febuxostat dose) and liver function tests abnormalities 
(4%–6%). In the latter case, the rates were not higher than 
those found with the fixed dose of allopurinol. Cardiovascular 
events were registered in similar rates across groups and no 
deaths during the study period were reported.
Limitations of the FACT study have been pointed out 
since its publication, and some of these are shared by 
the APEX trial. An editorial accompanying the FACT 
trial emphasized that the dose of allopurinol used for 
comparison (300 mg/day), which could not be modified 
to preserve the double-blind design, may have been 
insufficient for a real comparison of the urate-lowering 
efficacy of these two agents.49 Others have commented on 
the limited generalizability of the trial given the exclusion 
of patients with kidney dysfunction, a caveat that the 
APEX trial tried to address with an effort hampered by 
insufficient recruitment. Some authors pointed towards 
the need for close monitoring of the safety signals raised 
by febuxostat in the FACT study, mainly represented by 
the four deaths in the febuxostat groups.50,51 Fortunately, 
these were not confirmed in the APEX trial. A selection 
bias towards patients with a previous poor response to 
allopurinol is a possibility and finally, due to fact that the 
primary endpoints of this trial were biochemical (reductions 
in SUA) instead of clinical (ie, disease- rather than patient-
oriented outcomes), the study is difficult to apply to clinical 
practice where reductions in gout flares are of paramount 
interest for patients.
Three ancillary studies published in abstract form 
only are based on patients studied in these trials. Becker 
et al52 analyzed patients treated with febuxostat in the Core Evidence 2009:4 32
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FACT and APEX studies trying to clarify the relationship 
between postbaseline SUA, a measure of the amount of 
SUA reduction after initiation of therapy, and the risk 
of gout flare. Clear relationships were discerned-early 
in urate-lowering treatment with the risk of flare being 
highest in the subjects with the lowest average postbaseline 
SUA and lowest in those with the highest SUA. This inverse 
relationship of SUA and flare was demonstrable during the 
first 3–4 months of treatment but not after 6 months. By 
12 months of treatment, the relationship was reversed, so 
that flare rates were lowest in patients with the lowest SUA. 
These differences were significant by trend analyses. The 
same author presented data from 182 African-American 
patients enrolled in the FACT trial or another 28-week 
phase III study (APEX) and showed that these patients 
achieved SUA targets of 6.0 mg/dL or less in the same 
proportions as the overall FACT population. Schumacher 
et al,53 using the same base of patients from the FACT and 
APEX trials, focused on individuals over 65 years old. A total 
of 295 patients were studied, with reports of good tolerance 
and efficacy in achieving a target SUA of 6.0 mg/dL or less 
in the majority of the population.
The EXCEL study is an open-label phase III extension 
of the FACT study that, along with additional enrolled 
patients, is randomizing 735 patients to febuxostat 80 or 
120 mg/day or allopurinol 300 mg/day in a 2:2:1 ratio 
to continue evaluating treatment response. Two interim 
analyses have been published in abstract form, and report 
that continuous reduction of SUA to levels of 6.0 mg/dL 
or less lead to significant clinical benefits, and that a larger 
proportion of patients receiving allopurinol treatment 
compared with febuxostat 80 and 120 mg/day failed to 
achieve this goal.54,55 Finally, abstracts from two Japanese 
phase III studies reported that febuxostat 20 and 40 mg/day 
reduced SUA in a dose-dependent manner compared with 
placebo in 103 patients56 and that febuxostat 40 mg/day was 
more effective in reducing SUA than allopurinol 100 mg 
twice a day in 256 patients.57
In October 2008 the most recent clinical trial of 
febuxostat was presented at the Annual Meeting of the 
American College of Rheumatology. This 28-week 
phase III randomized, controlled, multicenter, double-blind 
trial comparing efficacy and safety of daily febuxostat 
and allopurinol in subjects with gout (CONFIRMS) trial 
randomized 2269 patients to receive febuxostat 40 mg/day, 
febuxostat 80 mg/day, or allopurinol 200 or 300 mg/day 
depending on renal function (patients with glomerular 
filtration rate of 30–59 mL/min received 200 mg/day of 
allopurinol).58 The primary endpoint was the proportion 
of patients achieving an SUA of less than 6 mg/dL at the 
end of follow up. A secondary endpoint analyzed this 
same outcome in those patients with mild or moderate 
renal dysfunction defined as glomerular filtration rates 
of 60–89 and 30–59 mL/min, respectively. As in most of 
the previous febuxostat trials, a majority of the subjects 
were middle-aged, (mean age 52.8 years) white males. 
Baseline SUA was 9.6 mg/dL and gout duration on 
average was 11.6 years. One thousand four hundred 
and eighty-three individuals had mild or moderate renal 
dysfunction. Urate lowering efficacy was similar with 
allopurinol 300 mg/day (42% achieved primary endpoint) 
and febuxostat 40 mg/day (45% achieved primary end-
point) but febuxostat 80 mg/day was statistically superior 
to the other two groups (67% achieved primary endpoint). 
Among patients with renal dysfunction febuxostat 80 mg/
day achieved the primary endpoint in a higher proportion 
of patients (72%) than in those taking febuxostat 40 mg/
day (50%) or allopurinol (42%). Rates of adverse events 
were comparable across groups and at all levels of renal 
function. Specifically, no difference was reported in the 
rate of cardiovascular events (six events were reported: 
three in the allopurinol arm and three in the febuxostat 
80 mg/day group). Five deaths occurred during the study, 
one in each febuxostat group and three in the allopurinol 
arm. CONFIRMS also provided additional evidence than 
that provided by the FACT and APEX trials supporting 
a stronger urate-lowering potency in the tested doses of 
febuxostat compared with allopurinol for those individuals 
with SUA greater than 10 mg/dL or with tophi.
Economic evidence and resource 
utilization
No economic studies of febuxostat have been published in 
peer-reviewed literature. Febuxostat was approved for its 
marketing in the European Union by the European Medicines 
Agency in April 2008 under the brand name Adenuric for 
the indication of “Treatment of chronic hyperuricemia in 
conditions where urate deposition has already occurred 
(including a history, or presence of, tophus and/or gouty 
arthritis).”59 Following this approval the National Institute 
for Health and Clinical Excellence (NICE) in the United 
Kingdom released its final appraisal determination for 
febuxostat in August 2008.60 As part of the report, a discus-
sion of an economic analysis performed by the manufacturer 
of febuxostat was presented, in which febuxostat at doses 
of 80 and 120 mg/day was compared with allopurinol Core Evidence 2009:4 33
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at 300 mg/day over time horizons of 1 and 2 years. The 
incremental cost-effectiveness ratios were £16 574 ($US25 
920) and £15 565 ($US24 342) per quality-adjusted life-year 
(QALY), respectively. The ad-hoc committee from NICE 
questioned this report on several levels based on what they 
considered to be imprecise estimates and biases. Considering 
this and the available clinical evidence its approval was 
finally issued “as an option for the management of chronic 
hyperuricemia in gout only for people who are intolerant of 
allopurinol or for whom allopurinol is contraindicated.” The 
manufacturer of febuxostat (Ipsen Pharmaceuticals) filed an 
appeal to this appraisal that is being processed at time of 
writing.61 Febuxostat was approved for marketing in the US 
in February 2009 under the brand name, Uloric®. Febuxostat’s 
market cost is likely to be substantially higher than its 
primary competitor, allopurinol, which is available as a 
generic prescription in the US ($US8.09 for a 30-day supply 
of 300 mg/day). Additional costs of febuxostat are still 
unclear as reports of liver function test abnormalities need 
further confirmation, but it appears that the usual laboratory 
monitoring performed with allopurinol to assure that kidney 
function is stable and that no liver function abnormalities 
are present will be also necessary with febuxostat. Also, 
reports about acute gout flares after initiation of febuxostat 
happening at least as often as with allopurinol makes the 
expected cost of gout flare prophylaxis the same for both 
groups, if not somewhat greater with febuxostat.
Patient group/population
Allopurinol allergy and intolerance
In general, allopurinol is usually well tolerated. However, 
patients with significant toxicities precluding its use have 
few, if any, alternatives since uricosurics are rarely used 
in clinical practice and may also be contraindicated in 
some of these patients. Because febuxostat has a chemical 
structure unrelated to that of allopurinol, the probability 
of developing cross-related intolerance to febuxostat is in 
theory low. Indeed, studies that have reported specifically on 
allopurinol-intolerant patients have described good results 
with febuxostat.
Chronic kidney disease
Uricosurics lose effectiveness in patients with glomerular 
filtration rates of less than 50 mL/min, and the frequency 
of allopurinol adverse effects rises sharply in patients with 
kidney dysfunction, leading to frequent undertreatment 
of hyperuricemia in patients with gout and kidney 
dysfunction.28,62 In the few patients with chronic kidney 
disease studied, febuxostat has had a safe profile with the 
caveat that, to date, chronic kidney disease patients have 
been underrepresented in trials. Preliminary results from the 
CONFIRMS study provided additional information about 
febuxostat being efficacious and reasonably safe in the short 
term in patients with moderate kidney dysfunction.
Solid organ transplant
As described above, patients with solid organ transplants 
have a higher frequency of hyperuricemia and tophaceous 
gout. Use of uricosurics and allopurinol may be limited 
due to comorbidities and multiple drug interactions. To 
our knowledge, febuxostat has not yet been tested in these 
patients, but it would represent a welcome addition to the 
currently limited therapeutic armamentarium in this clinical 
setting.
Outcomes summary
Gout continues to significantly affect the quality of life of 
millions of middle-aged and elderly adults. Its causative 
metabolic abnormality, hyperuricemia, has been associated 
with other conditions that are important contributors to the 
population morbidity and mortality and which prevalence are 
increasing, like the metabolic syndrome, hypertension and 
chronic kidney disease.63–65 The incidence of both hyperuri-
cemia and gout could also be expected to rise with an aging 
population with cardiovascular risk factors.
Until February 2009, there were few tenable therapeutic 
alternatives for gout, and no new drug for its management had 
been approved in the US since allopurinol in 1964. Uricosuric 
drugs are of limited application in clinical practice because 
of inefficacy, adverse effects, and drug interactions. Allopu-
rinol has the main advantage of having been in the market 
for several decades, having generally good tolerability, low 
frequency of adverse events, and being rather inexpensive. 
However, there are patients, including those with chronic 
kidney disease and solid organ transplantations, in whom 
allopurinol efficacy is more commonly limited by drug 
interactions, adverse events, and under dosing. Furthermore, 
some patients may not tolerate allopurinol and a few may 
develop hypersensitivity. In these populations and others 
where hyperuricemia and gout tends to be more prevalent and 
disabling, a new addition to the treatment armamentarium 
would be most welcome.
The evidence for the use of febuxostat in gout is 
summarized in the table at the beginning of this review. 
Febuxostat, at doses between 80 and 120 mg/day, favorably 
compares with standard dose allopurinol in reducing SUA. Core Evidence 2009:4 34
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Nevertheless, questions still remain over this issue since a 
double-blind study using as a comparator the commonly 
used “titration to effect” strategy for allopurinol has not 
been conducted. There has been a dearth of primary clinical 
outcomes (gout flares, number or size of tophi) in this first 
wave of febuxostat studies, as it is expected that the marked 
SUA-lowering effect translates into clinical improvement in 
real practice. However, this an important limitation of the 
phase III studies reported so far for this drug.
Concerns about the safety of febuxostat have been 
expressed. Initial cardiovascular safety signals raised 
in the FACT trial have not been replicated in recently 
released phase III trials. However, postmarketing surveil-
lance will be necessary to monitor for adverse events, 
given the well-known limitations of clinical trials on this 
respect.
In conclusion, febuxostat has been approved in the 
EU and US for the treatment of chronic hyperuricemia in 
conditions where urate deposition has already occurred, 
and it will likely find a niche in patients with gout who are 
unable to use allopurinol because of intolerances, adverse 
reaction, or drug-drug interactions. In addition, patients 
with tophaceous gout or with very high SUA levels (more 
than 10 mg/dL) may also benefit from the higher potency of 
febuxostat versus allopurinol (at the fixed dosages tested). 
A large proportion of these difficult-to-treat patients have 
chronic kidney disease and organ transplantations, and they 
are expected to benefit the most from additional alternatives 
for the management of chronic gout. However, allopurinol, 
given its cost and experience, with use will likely remain 
as the first-line drug for the management of gout in most 
patients.
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